Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4517 |
Name | skin angiosarcoma |
Definition | An angiosarcoma and hemangioma of skin and malignant skin vascular tumor and sarcoma of skin that is located_in the skin and results_in an enlarged bruise (a blue-black nodule) and an unhealed ulceration. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin sarcoma skin angiosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02780011 | Phase I | Alisertib + Brentuximab vedotin | Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies | Withdrawn | USA | 0 |
NCT03544567 | Phase I | Oraxol | A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma | Completed | USA | GBR | 2 |
NCT04339738 | Phase II | Cabozantinib + Nivolumab Nivolumab + Paclitaxel Paclitaxel | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | Active, not recruiting | USA | 1 |
NCT05799612 | Phase I | Filgrastim + mRNA plus lysate-loaded dendritic cell vaccine + Paclitaxel + Peg-interferon alfa-2a | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma | Withdrawn | 0 | |
NCT06273852 | Phase I | PBA-0405 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT06898970 | Phase II | Pembrolizumab + RP1 | Intratumoral Vusolimogene Oderparepvec (VO) in Combination with Pembrolizumab for Angiosarcoma | Not yet recruiting | USA | 0 |